Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves Β· freshest Wall Street data, updated daily View live feed β†’
Analyst Tracker/Yigal Nochomovitz
Citi

Yigal Nochomovitz

Wall Street Analyst
β˜…β˜…β˜…β˜†β˜†
#2242
on 13Foresight Β· ranked by our own returns
39%
Success Rate
-3.1%
Average Return
63 of 162 calls profitable Β· +24.3% vs benchmark
S&P 500 (SPY)
πŸ“ˆ Across the calls we could measure, roughly 39% of Yigal Nochomovitz's ratings turned a profit when each position was held for 2 year β€” averaging -3.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

233 Buy 9 Hold 9 Sell
Yigal's Stock Coverage 66 ratings Β· 2026-11-20
Company Date Position Consensus β“˜ Price Target β“˜ 2-Yr Return vs S&P 500 β“˜
LGND
Ligand Pharma
Oct 29, 2026 BUY Strong Buy
-11.1% avg upside
16 analysts
$397.00
23.10% Upside
-5.9% Β·
PROK
ProKidney
Oct 28, 2026 BUY Buy
+393.1% avg upside
12 analysts
$8.00
517.85% Upside
-27.6% Β·
ZBIO
Zenas BioPharma, Inc.
Oct 27, 2026 BUY Strong Buy
+52.5% avg upside
11 analysts
$48.00
69.12% Upside
-8.3% Β·
ZYME
Zymeworks
Oct 27, 2026 BUY Strong Buy
+18.3% avg upside
26 analysts
$39.00
36.29% Upside
-10.4% Β·
SMMT
Summit Therapeutics
Oct 26, 2026 BUY Strong Buy
+83.3% avg upside
29 analysts
$43.00
168.17% Upside
-26.4% Β·
RCUS
Arcus Biosciences
Oct 25, 2026 BUY Strong Buy
+99.0% avg upside
22 analysts
$50.00
174.95% Upside
-7.7% Β·
LXRX
Lexicon Pharmaceuticals
Oct 25, 2026 BUY Buy
+216.4% avg upside
10 analysts
$3.10
118.24% Upside
+22.8% Β·
AVBP
ArriVent BioPharma, Inc.
Oct 23, 2026 BUY Strong Buy
+89.4% avg upside
15 analysts
$20.00
34.44% Upside
-49.9% Β·
EYPT
EyePoint Pharmaceuticals
Oct 20, 2026 BUY Buy
+3222.9% avg upside
21 analysts
$4.00
1048.15% Upside
-26.8% Β·
ONC
BeOne Medicines
Oct 19, 2026 BUY Strong Buy
-1.2% avg upside
29 analysts
$466.00
25.75% Upside
+8.0% Β·
ZLAB
Zai Lab
Oct 19, 2026 BUY Strong Buy
+170.5% avg upside
13 analysts
$45.00
103.97% Upside
-7.9% Β·
KRYS
Krystal Biotech
Oct 16, 2026 BUY Strong Buy
-15.2% avg upside
20 analysts
$416.00
25.12% Upside
-0.2% Β·
AAPG
Ascentage Pharma Group International Unsponsored ADR
Oct 15, 2026 BUY Strong Buy
+211.5% avg upside
11 analysts
$46.00
218.12% Upside
-9.5% Β·
BMEA
Biomea Fusion
Oct 14, 2026 BUY Strong Buy
+1905.8% avg upside
16 analysts
$7.00
994.67% Upside
-41.0% Β·
MIRM
Mirum Pharmaceuticals
Oct 13, 2026 BUY Strong Buy
+48.1% avg upside
24 analysts
$184.00
116.51% Upside
+20.0% Β·
ATTO
Attovia Therapeutics, Inc.
Oct 13, 2026 BUY Strong Buy
+161.7% avg upside
4 analysts
$30.00
97.54% Upside
+2.8% Β·
SNDX
Syndax Pharmaceuticals
Oct 13, 2026 BUY Strong Buy
+155.4% avg upside
27 analysts
$57.00
317.65% Upside
-34.1% Β·
SPTX
Seaport Therapeutics, Inc.
Oct 07, 2026 BUY Strong Buy
+90.0% avg upside
9 analysts
$35.00
78.49% Upside
+2.2% Β·
SRPT
Sarepta Therapeutics
Sep 27, 2026 SELL Buy
+223.8% avg upside
50 analysts
$13.00
30.20% Downside
+24.6% Β·
ACAD
ACADIA Pharmaceuticals
Sep 25, 2026 BUY Strong Buy
+71.5% avg upside
43 analysts
$33.00
60.25% Upside
-11.4% Β·
ARCT
Arcturus Therapeutics
Sep 24, 2026 BUY Buy
+175.7% avg upside
36 analysts
$20.00
81.36% Upside
-43.1% Β·
RARE
Ultragenyx Pharmaceutical
Sep 18, 2026 BUY Buy
+193.8% avg upside
36 analysts
$32.00
98.74% Upside
+15.1% Β·
OLMA
Olema Pharmaceuticals
Sep 13, 2026 BUY Strong Buy
+401.3% avg upside
16 analysts
$59.00
742.76% Upside
-29.8% Β·
SLDB
Solid Biosciences
Sep 10, 2026 BUY Strong Buy
+176.4% avg upside
26 analysts
$14.00
125.72% Upside
-31.3% Β·
IDYA
IDEAYA Biosciences
Sep 10, 2026 BUY Strong Buy
+48.2% avg upside
31 analysts
$65.00
103.42% Upside
-26.8% Β·
KRRO
Korro Bio
Sep 09, 2026 BUY Strong Buy
+90.0% avg upside
19 analysts
$21.00
46.77% Upside
-4.7% Β·
CRSP
Crispr Therapeutics AG
Sep 04, 2026 BUY Buy
+45.6% avg upside
41 analysts
$88.00
71.14% Upside
-28.0% Β·
NBIX
Neurocrine
Sep 04, 2026 BUY Strong Buy
+27.3% avg upside
37 analysts
$253.00
73.23% Upside
+6.6% Β·
LENZ
LENZ Therapeutics
Aug 13, 2026 BUY Buy
+470.0% avg upside
17 analysts
$10.00
227.92% Upside
-27.4% Β·
CRBU
Caribou Biosciences
Aug 13, 2026 BUY Strong Buy
+1510.4% avg upside
13 analysts
$8.00
1790.44% Upside
-78.9% Β·
STTK
Shattuck Labs
Aug 12, 2026 BUY Strong Buy
+276.2% avg upside
16 analysts
$18.00
223.76% Upside
-40.5% Β·
ARDX
Ardelyx
Aug 10, 2026 BUY Strong Buy
+324.2% avg upside
21 analysts
$11.00
263.00% Upside
-25.1% Β·
ARVN
Arvinas Holding Company
Aug 10, 2026 BUY Buy
+257.9% avg upside
28 analysts
$21.00
167.19% Upside
-24.1% Β·
RIGL
Rigel
Aug 06, 2026 BUY Buy
-47.4% avg upside
17 analysts
$83.00
61.68% Upside
+9.4% Β·
TVTX
Travere Therapeutics
Aug 06, 2026 BUY Strong Buy
+15.5% avg upside
22 analysts
$85.00
68.75% Upside
-18.2% Β·
CADL
Candel Therapeutics
Jun 30, 2026 BUY Strong Buy
+134.0% avg upside
12 analysts
$26.00
212.19% Upside
-47.6% Β·
ORIC
Oric Pharmaceuticals
May 05, 2026 BUY Strong Buy
+160.3% avg upside
21 analysts
$16.00
73.17% Upside
-16.4% Β·
DRTS
Alpha Tau
Mar 10, 2026 BUY Strong Buy
+7.2% avg upside
5 analysts
$9.00
31.18% Downside
+76.8% Β·
SGP
SpyGlass Pharma
Mar 09, 2026 BUY Strong Buy
+36.5% avg upside
6 analysts
$42.00
30.22% Upside
+9.4% Β·
PRQR
ProQR
Mar 07, 2025 BUY Strong Buy
+683.4% avg upside
19 analysts
$4.00
187.73% Upside
-39.8% Β·
CLLS
Cellectis SA
Dec 11, 2024 BUY Strong Buy
+1837.3% avg upside
16 analysts
$11.00
918.45% Upside
-44.2% Β·
CHRS
Coherus Biosciences
Dec 04, 2024 BUY Buy
+1336.6% avg upside
19 analysts
$8.00
863.81% Upside
-71.9% Β·
CYVNY
Ceryvyn Therapeutics Limited
Sep 12, 2024 BUY Hold
+41566.6% avg upside
7 analysts
$10.00
55455.52% Upside
Β· Β·
MGNX
MacroGenics
Aug 15, 2024 BUY Strong Buy
+638.9% avg upside
25 analysts
$14.00
483.31% Upside
+29.4% Β·
OVID
Ovid Therapeutics
Jun 17, 2024 HOLD Strong Buy
+103.8% avg upside
19 analysts
$1.20
52.81% Downside
+206.3% Β·
FATE
Fate Therapeutics
May 15, 2024 BUY Buy
+482.8% avg upside
31 analysts
$10.00
380.73% Upside
-58.5% Β·
ALDX
Aldeyra Therapeutics
Dec 04, 2023 BUY Strong Buy
+2746.2% avg upside
21 analysts
$8.00
1327.73% Upside
+49.2% Β·
ATRA
Atara Biotherapeutics
Nov 22, 2023 SELL Buy
+125.9% avg upside
18 analysts
$10.00
24.85% Upside
+4.3% Β·
IPHA
Innate Pharma
Sep 18, 2023 BUY Strong Buy
+381.8% avg upside
10 analysts
$8.00
447.97% Upside
-29.4% Β·
OBX
Obsidian Therapeutics
Aug 29, 2023 HOLD Strong Buy
+14.6% avg upside
11 analysts
$0.25
98.40% Downside
Β· Β·
PTCT
PTC Therapeutics
May 24, 2023 BUY Buy
+35.4% avg upside
29 analysts
$63.00
5.04% Upside
-2.2% Β·
NCNA
Nucana
Nov 28, 2022 BUY Buy
+1147.5% avg upside
9 analysts
$2.00
98.10% Upside
Β· Β·
FR:IPH
Innate Pharma SA
Sep 16, 2022 BUY Strong Buy
+603.3% avg upside
5 analysts
$12.00
855.40% Upside
-20.9% Β·
ELVN
Enliven Therapeutics
Apr 05, 2022 HOLD Strong Buy
+40.0% avg upside
18 analysts
$8.00
81.85% Downside
+281.9% Β·
PBYI
Puma Biotechnology
Sep 27, 2021 BUY Hold
+305.2% avg upside
11 analysts
$11.00
5.39% Upside
-62.4% Β·
SYBX
Synlogic
Aug 21, 2019 SELL Buy
+2407.5% avg upside
11 analysts
$2.00
108.39% Upside
Β· Β·
AKBA
Akebia Therapeutics
Mar 20, 2019 HOLD Strong Buy
+1184.7% avg upside
16 analysts
$9.00
1173.87% Upside
-59.3% Β·
ANTH
Anthera Pharmaceuticals
Dec 29, 2016 HOLD Buy
+4728471.4% avg upside
9 analysts
β€” Β· Β·
NTBLQ
Notable Labs
Aug 13, 2015 HOLD Buy
+809999900.0% avg upside
12 analysts
β€” Β· Β·
VSTM
Verastem
Apr 27, 2015 HOLD Strong Buy
+55.8% avg upside
24 analysts
β€” Β· Β·
ENLV
Enlivex
Mar 31, 2015 BUY Strong Buy
+2278.3% avg upside
4 analysts
$32.00
1697.79% Upside
Β· Β·
OCUL
Ocular Therapeutix
Mar 30, 2015 BUY Strong Buy
+253.9% avg upside
21 analysts
$49.00
602.99% Upside
-78.4% Β·
KPTI
Karyopharm Therapeutics
Mar 16, 2015 BUY Strong Buy
+2682.1% avg upside
18 analysts
$53.00
7906.06% Upside
Β· Β·
LSTA
Lisata Therapeutics
Jan 09, 2015 BUY Buy
+1169.6% avg upside
11 analysts
$10.00
880.47% Upside
Β· Β·
SLS
SELLAS Life Sciences Group
Nov 23, 2014 HOLD Strong Buy
+606.9% avg upside
16 analysts
β€” Β· Β·
IL:KMDA
Kamada
Nov 21, 2014 HOLD Strong Buy
+62.6% avg upside
7 analysts
β€” +65.8% Β·
πŸ”’ 61 more ratings β€” with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Yigal Nochomovitz β€” Frequently Asked Questions
How accurate are Yigal Nochomovitz's stock ratings?
Based on the calls 13Foresight could measure, about 39% of Yigal's ratings were profitable over a one-year hold, with an average return of -3.2% per rating, or +23.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Yigal ranked on 13Foresight?
Yigal Nochomovitz is currently ranked #2242 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge β€” so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Yigal cover?
Yigal most recently has ratings on LGND, PROK, ZBIO, ZYME, SMMT, RCUS, LXRX, AVBP, EYPT, ONC, ZLAB, KRYS and 54 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.